Overview of Dry Age-Related Macular Degeneration (Dry AMD)

Overview of Dry Age-Related Macular Degeneration (Dry AMD)

Dry age-related macular degeneration is a widespread eye disorder that affects the macula, the central portion of the retina responsible for clear and focused vision. The condition becomes more complex when accompanied by severe retinal deterioration, genetic factors, or other coexisting medical conditions that complicate treatment and heighten the risk of significant vision loss. Common symptoms include a gradual decline in central vision, difficulty seeing in dim lighting, and the appearance of a central blind spot. As the disease progresses, these symptoms can intensify, leading to substantial visual impairment.

Although there is currently no cure for dry AMD, treatment aims to slow disease progression. The most widely used approach involves nutritional supplements rich in specific vitamins and minerals, which may help reduce advancement in certain individuals. In addition, lifestyle modifications—like quitting smoking and following a diet high in leafy greens and omega-3s—can also support disease management. Routine eye checkups are crucial for tracking changes and identifying early signs of wet AMD, a more advanced form of the disease. While vision loss from dry AMD is irreversible, early diagnosis and appropriate care are essential for preserving remaining sight and supporting a good quality of life.

Get the facts at a glance—view our new infographic

https://www.delveinsight.com/infographics/age-related-macular-degeneration-amd-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

Epidemiological Segmentation of Dry AMD (2020–2034, 7MM)

• Overall prevalence
  
  

• Stage-based prevalence
  
  

• Total cases of geographic atrophy
  
  

• Diagnosed prevalence
  
  

• Age-based prevalence for early and intermediate stages
  
  

• Age-specific geographic atrophy cases
  
  

• Geographic atrophy cases categorized by visual impairment
  
  

Dry AMD Epidemiology

• The total number of AMD cases in the 7 major markets (7MM) is estimated at approximately 68 million.
  
  

• The U.S. accounts for 31% of these cases.
  
  

• In Japan, individuals aged 85 and older represent 40% of geographic atrophy cases.
  
  

From insights to impact— Read the full report now

Dry AMD Market Snapshot

• Market Size (2023, 7MM): Approximately USD 1.3 billion
  
  

Market Growth Drivers

• Expanding pipeline with peptide-based drugs, monoclonal antibodies, gene therapies, and stem cell approaches targeting key disease mechanisms.
  
  

• The largely untapped dry AMD segment presents opportunities comparable to those seen in the wet AMD market.
  
  

• Progress in cell therapy and HtrA (high-temperature requirement A) inhibitors is propelling development efforts.
  
  

• Increasing focus on innovative treatment options is fostering research and investment.
  
  

Market Challenges

• Lack of clearly defined clinical endpoints slows the development and approval of new therapies.
  
  

• High costs associated with advanced treatments hinder patient access and insurance coverage.
  
  

• The complex nature of the disease poses obstacles to both diagnosis and management.
  
  

• Limited awareness and the absence of approved therapies delay timely diagnosis and care.
  
  

One graphic, all the essentials— Click to explore

Emerging Therapies for Dry AMD

• Iptacopan
  
  

• Elamipretide
  
  

• IONIS-FB-LRx
  
  

• Additional promising candidates
  
  

Key Companies in the Dry AMD Space

• Novartis
  
  

• Stealth BioTherapeutics
  
  

• Ionis Pharmaceuticals / Roche
  
  

• And others
  
  

What do these trends mean for the future? Find out in the full report

https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr